

Date: 4-August-2024

News Coverage of Press Release

“Pfizer’s Assets Acquisition, CCP Grants Approval”

CCP grants approval **Lucky Core acquiring certain assets of Pfizer**

RECORDER REPORT

ISLAMABAD: The Competition Commission of Pakistan (CCP) has approved the acquisition of certain assets of M/s. Pfizer Pakistan Limited by M/s. Lucky Core Industries. This acquisition is facilitated by a set of agreements including the frame agreement and asset purchase agreements.

The acquisition encompasses several well-known pharmaceutical products and their respective registrations, manufacturing technology, know-how, and associated trademarks for Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and Mycitracin.

Lucky Core Industries, a publicly listed company in Pakistan, is engaged in manufacturing various chemicals and pharmaceuticals.

The Seller, Pfizer Pakistan Limited, is a public unlisted company that manufactures, imports, and markets pharmaceutical products in Pakistan. Its parent company, M/s. Pfizer Inc, is a publicly listed biopharmaceutical and biotechnology company based in Delaware, USA.

The CCP's market assessment identified the relevant product markets as 'Antirheumatic Systemic, Vitamins, Systemic Corticosteroids, Cough & Cold Preparations, Antiprotozoal & Anthelmintic, and Topical Antibacterial & Antivirals', with the geographic market being Pakistan.

This transaction is classified as a horizontal merger, resulting in a minor increase in the market presence of Lucky Core Industries across the relevant markets.

The CCP has determined that the acquisition will not lead to dominance in any market, thus granting swift approval.

This strategic acquisition is poised to enhance the technological advancement in Pakistan's pharmaceutical sector, fostering innovation and ensuring a competitive market landscape.

The CCP's approval underlines its commitment to upholding fair competition, benefiting consumers, and encouraging growth and investment in the industry.

Approval given to Lucky Core to acquire certain Pfizer assets: CCP

By our correspondent

KARACHI: Lucky Core Industries has secured approval from the Competition Commission of Pakistan (CCP) to acquire certain assets of Pfizer Pakistan Limited.

This acquisition, facilitated through the frame agreement and asset purchase agreements, includes several prominent pharmaceutical products along with their registrations, manufacturing technology, and associated trademarks.

The assets in question encompass well-known products such as Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and Mycitracin.

Lucky Core Industries, a publicly listed company in Pakistan, specializes in manufacturing chemicals and pharmaceuticals.

Pfizer Pakistan Limited, the seller, is a public unlisted company engaged in the production, import, and marketing of pharmaceutical products within Pakistan. Pfizer Pakistan's parent company, Pfizer Inc, is a major biopharmaceutical and biotechnology firm based in Delaware, USA.

In its market assessment, the CCP identified the relevant product markets as including antirheumatic systemic, vitamins, systemic corticosteroids, cough & cold preparations, antiprotozoal and anthelmintic, and topical antibacterial and antivirals, with the geographic focus being Pakistan.

The transaction, categorized as a horizontal merger, will result in a modest increase in Lucky Core Industries' market presence across these segments. The CCP concluded that this acquisition will not result in market dominance and thus approved the transaction without delay.

This strategic move is expected to advance technological capabilities within Pakistan's pharmaceutical sector, promote innovation, and support a competitive market environment.

The CCP's decision reflects its dedication to maintaining fair competition, benefiting consumers, and fostering growth and investment in the industry.

CCP approves acquisition of certain assets of Pfizer by Lucky Core Industries

IMRAN ALI KUNDI
ISLAMABAD

The Competition Commission of Pakistan (CCP) has approved the acquisition of certain assets of M/s. Pfizer Pakistan Limited by M/s. Lucky Core Industries. This acquisition is facilitated by a set of agreements including the Frame Agreement and Asset Purchase Agreements.

The acquisition encompasses several well-known pharmaceutical products and their respective registrations, manufacturing technology, know-how, and associated trademarks for AnsaId, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and MycitraCin. Lucky Core Industries, a publicly listed company in Pakistan, is engaged in manufacturing various chemicals and pharmaceuticals. The seller, Pfizer Pakistan Limited, is a public unlisted company that manufactures, imports, and markets pharmaceutical products in Pakistan. Its parent company, M/s. Pfizer Inc., is a publicly listed biopharmaceutical and biotechnology company based in Delaware, USA.

The CCP's market assessment identified the relevant product markets as 'Antirheumatic Systemic, Vitamins, Systemic Corticosteroids, Cough & Cold Preparations, Antiprotozoal & Anthelmintic, and Topical Antibacterial & Antivirals', with the geographic market being Pakistan.

This transaction is classified as a horizontal merger, resulting in a minor increase in the market presence of Lucky Core Industries across the relevant markets. The CCP has determined that the acquisition will not lead to dominance in any market, thus granting swift approval. This strategic acquisition is poised to enhance the technological advancement in Pakistan's pharmaceutical sector, fostering innovation and ensuring a competitive market landscape. The CCP's approval underlines its commitment to upholding fair competition, benefiting consumers, and encouraging growth and investment in the industry.

CCP greenlights Lucky Core Industries' acquisition of Pfizer Pakistan assets

ISLAMABAD

MONITORING DESK

The Competition Commission of Pakistan (CCP) has approved Lucky Core Industries' (LCI) acquisition of specific assets from Pfizer Pakistan Limited. This deal, facilitated through a series of agreements including the Frame Agreement and Asset Purchase Agreements, involves several prominent pharmaceutical products and their registrations, manufacturing technology, know-how, and associated trademarks. The products include Ansaïd, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and Mycitracin. LCI, a publicly traded company in Pakistan, specializes in the production of chemicals and pharmaceuticals. Pfizer Pakistan Limited, the seller, is a public unlisted company engaged in the manufacturing, importing, and marketing of pharmaceuticals within Pakistan. Its parent company, Pfizer Inc., is a publicly traded biopharmaceutical and biotechnology firm based in Delaware, USA. The CCP's market analysis identified the relevant product markets as Antirheumatic Systemic, Vitamins, Systemic Corticosteroids, Cough & Cold Preparations, Antiprotozoal & Anthelmintic, and Topical Antibacterial & Antivirals, with Pakistan as the geographic market. Classified as a horizontal merger, this transaction is expected to slightly boost LCI's market presence across the relevant sectors. The CCP concluded that the acquisition would not result in market dominance, leading to prompt approval. This strategic move is set to advance technological capabilities in Pakistan's pharmaceutical industry, promoting innovation and maintaining a competitive market environment.

4-August-2024

Online

HEALTH

Pfizer's Assets Acquisition, CCP Grants Approval

03/08/2024

ISLAMABAD, /DNA/ – The Competition Commission of Pakistan (CCP) has approved the acquisition of certain assets of M/s. Pfizer Pakistan Limited by M/s. Lucky Core Industries. This acquisition is facilitated by a set of agreements including the Frame Agreement and Asset Purchase Agreements.

The acquisition encompasses several well-known pharmaceutical products and their respective registrations, manufacturing technology, know-how, and associated trademarks for Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and Mycitracin.

Lucky Core Industries, a publicly listed company in Pakistan, is engaged in manufacturing various chemicals and pharmaceuticals. The Seller, Pfizer Pakistan Limited, is a public unlisted company that manufactures, imports, and markets pharmaceutical products in Pakistan. Its parent company, M/s. Pfizer Inc., is a publicly listed biopharmaceutical and biotechnology company based in Delaware, USA.

The CCP's market assessment identified the relevant product markets as 'Antirheumatic Systemic, Vitamins, Systemic Corticosteroids, Cough & Cold Preparations, Antiprotozoal & Anthelmintic, and Topical Antibacterial & Antivirals', with the geographic market being Pakistan.

This transaction is classified as a horizontal merger, resulting in a minor increase in the market presence of Lucky Core Industries across the relevant markets. The CCP has determined that the acquisition will not lead to dominance in any market, thus granting swift approval.

This strategic acquisition is poised to enhance the technological advancement in Pakistan's pharmaceutical sector, fostering innovation and ensuring a competitive market landscape. The CCP's approval underlines its commitment to upholding fair competition, benefiting consumers, and encouraging growth and investment in the industry.

<https://islamabadpost.com.pk/pfizers-assets-acquisition-ccp-grants-approval/>

4-August-2024

Business Page

Pfizer's Assets Acquisition, CCP Grants Approval

Commerce Desk

ISLAMABAD: The Competition Commission of Pakistan (CCP) has approved the acquisition of certain assets of M/s. Pfizer Pakistan Limited by M/s. Lucky Core Industries. This acquisition is facilitated by a set of agreements including the Frame Agreement and Asset Purchase Agreements.

The acquisition encompasses several well-known pharmaceutical products and their respective registrations, manufacturing technology, know-how, and associated trademarks for Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and Mycitraicin.

Lucky Core Industries, a publicly listed company in Pakistan, is engaged in manufacturing various chemicals and pharmaceuticals. The Seller, Pfizer Pakistan Limited, is a public unlisted company that manufactures, imports, and markets pharmaceutical products in Pakistan. Its parent company, M/s. Pfizer Inc., is a publicly listed biopharmaceutical and biotechnology company based in Delaware, USA.

The CCP's market assessment identified the relevant product markets as 'Antirheumatic Systemic, Vitamins, Systemic Corticosteroids, Cough & Cold Preparations, Antiprotozoal & Anthelmintic, and Topical Antibacterial & Antivirals', with the geographic market being Pakistan.

This transaction is classified as a horizontal merger, resulting in a minor increase in the market presence of Lucky Core Industries across the relevant markets. The CCP has determined that the acquisition will not lead to dominance in any market, thus granting swift approval.

This strategic acquisition is poised to enhance the technological advancement in Pakistan's pharmaceutical sector, fostering innovation and ensuring a competitive market landscape. The CCP's approval underlines its commitment to upholding fair competition, benefiting consumers, and encouraging growth and investment in the industry.

CCP Approves Lucky Core Industries' Acquisition of Pfizer Pakistan Assets

By ProPK Staff | Published Aug 5, 2024 | 12:00 pm



Lucky Core Industries will acquire certain assets of M/s. Pfizer Pakistan Limited after approval of the Competitive Commission of Pakistan.

This acquisition is facilitated by a set of agreements including the Frame Agreement and Asset Purchase Agreements. The acquisition encompasses several well-known pharmaceutical products and their respective registrations, manufacturing technology, know-how, and associated trademarks for Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and Mycitracin.

Lucky Core Industries, a publicly listed company in Pakistan, is engaged in manufacturing various chemicals and pharmaceuticals. The Seller, Pfizer Pakistan Limited, is a public unlisted company that manufactures, imports, and markets pharmaceutical products in Pakistan. Its parent company, M/s. Pfizer Inc. is a publicly listed biopharmaceutical and biotechnology company based in Delaware, USA.

The CCP's market assessment identified the relevant product markets as 'Antirheumatic Systemic, Vitamins, Systemic Corticosteroids, Cough & Cold Preparations, Antiprotozoal & Anthelmintic, and Topical Antibacterial & Antivirals', with the geographic market being Pakistan. This transaction is classified as a horizontal merger, resulting in a minor increase in the market presence of Lucky Core Industries across the relevant markets.

The CCP has determined that the acquisition will not lead to dominance in any market, thus granting swift approval. This strategic acquisition is poised to enhance the technological advancement in Pakistan's pharmaceutical sector, fostering innovation and ensuring a competitive market landscape. The CCP's approval underlines its commitment to upholding fair competition, benefiting consumers, and encouraging growth and investment in the industry.

<https://propakistani.pk/2024/08/05/ccp-approves-lucky-core-industries-acquisition-of-pfizer-pakistan-assets/>



4-August-2024

Online

Pfizer's Assets Acquisition, CCP Grants Approval

Lucky Core Industries, a publicly listed company, is engaged in manufacturing various chemicals and pharmaceuticals.

ON: AUGUST 5, 2024 / IN: COMMERCE AND INDUSTRY / TAGGED: APPROVED ACQUISITION, COMPETITION COMMISSION, LUCKY CORE INDUSTRIES, PFIZER PAKISTAN LIMITED



Pfizer's Assets Acquisition, CCP Grants Approval

Lucky Core Industries, a publicly listed company in Pakistan, is engaged in manufacturing various chemicals and pharmaceuticals.

ISLAMABAD (WEB NEWS)

The Competition Commission of Pakistan (CCP) has approved the acquisition of certain assets of M/s. Pfizer Pakistan Limited by M/s. Lucky Core Industries. This acquisition is facilitated by a set of agreements including the Frame Agreement and Asset Purchase Agreements.

The acquisition encompasses several well-known pharmaceutical products and their respective registrations, manufacturing technology, know-how, and associated trademarks for Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and Mycitracin.

Lucky Core Industries, a publicly listed company in Pakistan, is engaged in manufacturing various chemicals and pharmaceuticals. The Seller, Pfizer Pakistan Limited, is a public unlisted company that manufactures, imports, and markets pharmaceutical products in Pakistan. Its parent company, M/s. Pfizer Inc., is a publicly listed biopharmaceutical and biotechnology company based in Delaware, USA.

The CCP's market assessment identified the relevant product markets as 'Antirheumatic Systemic, Vitamins, Systemic Corticosteroids, Cough & Cold Preparations, Antiprotozoal & Anthelmintic, and Topical Antibacterial & Antivirals', with the geographic market being Pakistan.

This transaction is classified as a horizontal merger, resulting in a minor increase in the market presence of Lucky Core Industries across the relevant markets. The CCP has determined that the acquisition will not lead to dominance in any market, thus granting swift approval.

This strategic acquisition is poised to enhance the technological advancement in Pakistan's pharmaceutical sector, fostering innovation and ensuring a competitive market landscape. The CCP's approval underlines its commitment to upholding fair competition, benefiting consumers, and encouraging growth and investment in the industry.

<https://www.telecoalert.com/2024/08/05/pfizers-assets-acquisition-ccp-grants-approval/>

4-August-2024
Online

Pfizer Pakistan's assets to be acquired by LCI, CCP approves



August 04, 2024 (MLN): The Competition Commission of Pakistan (CCP) has approved the acquisition of certain assets of Pfizer Pakistan Limited by Lucky Core Industries (PSX: LCI).

This acquisition is facilitated by a set of agreements including the Frame Agreement and Asset Purchase Agreements.

The acquisition encompasses several well-known pharmaceutical products and their respective registrations, manufacturing technology, know-how, and associated trademarks for Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and Mycitracin.

LCI, a publicly listed company in Pakistan, is engaged in manufacturing various chemicals and pharmaceuticals.

The Seller, Pfizer Pakistan Limited, is a public unlisted company that manufactures, imports, and markets pharmaceutical products in Pakistan.

Its parent company, Pfizer Inc., is a publicly listed biopharmaceutical and biotechnology company based in Delaware, USA.

The CCP's market assessment identified the relevant product markets as 'Antirheumatic Systemic, Vitamins, Systemic Corticosteroids, Cough & Cold Preparations, Antiprotozoal & Anthelmintic, and Topical Antibacterial & Antivirals', with the geographic market being Pakistan.

This transaction is classified as a horizontal merger, resulting in a minor increase in the market presence of Lucky Core Industries across the relevant markets.

The CCP has determined that the acquisition will not lead to dominance in any market, thus granting swift approval.

This strategic acquisition is poised to enhance the technological advancement in Pakistan's pharmaceutical sector, fostering innovation and ensuring a competitive market landscape.

<https://mettisglobal.news/pfizer-pakistans-assets-to-be-acquired-by-lci-ccp-approves/>

4-August-2024

Online

CCP Approves A Mega Acquisition In Corporate Sector Allowing Lucky Core To Acquire Pfizer



By Javed Mahmood Published 24 Hours Ago



ISLAMABAD: The Competition Commission of Pakistan (CCP) has approved the acquisition of certain assets of M/s. Pfizer Pakistan Limited by M/s. Lucky Core Industries. This acquisition is facilitated by a set of agreements including the Frame Agreement and Asset Purchase Agreements.

The acquisition encompasses several well-known pharmaceutical products and their respective registrations, manufacturing technology, know-how, and associated trademarks for Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and Mycitraicin.

Lucky Core Industries, a publicly listed company in Pakistan, is engaged in manufacturing various chemicals and pharmaceuticals. The Seller, Pfizer Pakistan Limited, is a public unlisted company that manufactures, imports, and markets pharmaceutical products in Pakistan. Its parent company, M/s. Pfizer Inc., is a publicly listed biopharmaceutical and biotechnology company based in Delaware, USA.

The CCP's market assessment identified the relevant product markets as 'Antirheumatic Systemic, Vitamins, Systemic Corticosteroids, Cough & Cold Preparations, Antiprotozoal & Anthelmintic, and Topical Antibacterial & Antivirals', with the geographic market being Pakistan.

This transaction is classified as a horizontal merger, resulting in a minor increase in the market presence of Lucky Core Industries across the relevant markets. The CCP has determined that the acquisition will not lead to dominance in any market, thus granting swift approval.

<https://thetruthinternational.com/latest-updates/breaking-news/ccp-approves-a-mega-acquisition-in-corporate-sector-allowing-lucky-core-to-acquire-pfizer/>

4-August-2024

Online

Pfizer's Assets Acquisition, CCP Grants Approval

Lucky Core Industries, a publicly listed company in Pakistan, is engaged in manufacturing various chemicals and pharmaceuticals.



Khudayar Mohla

August 4, 2024



After examining all the codal formalities, Competition Commission of Pakistan (CCP) approved acquisition of certain assets of M/s. Pfizer Pakistan Limited by M/s. Lucky Core Industries.

It has been stated in a press release that the acquisition is facilitated by a set of agreements including the Frame Agreement and Asset Purchase Agreements.

The acquisition encompasses several well-known pharmaceutical products and their respective registrations, manufacturing technology, know-how, and associated trademarks for Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and Mycitracin.

Lucky Core Industries, a publicly listed company in Pakistan, is engaged in manufacturing various chemicals and pharmaceuticals. The Seller, Pfizer Pakistan Limited, is a public unlisted company that manufactures, imports, and markets pharmaceutical products in Pakistan. Its parent company, M/s. Pfizer Inc., is a publicly listed biopharmaceutical and biotechnology company based in Delaware, USA.

The CCP's market assessment identified the relevant product markets as 'Antirheumatic Systemic, Vitamins, Systemic Corticosteroids, Cough & Cold Preparations, Antiprotozoal & Anthelmintic, and Topical Antibacterial & Antivirals', with the geographic market being Pakistan.

This transaction is classified as a horizontal merger, resulting in a minor increase in the market presence of Lucky Core Industries across the relevant markets. The CCP has determined that the acquisition will not lead to dominance in any market, thus granting swift approval.

This strategic acquisition is poised to enhance the technological advancement in Pakistan's pharmaceutical sector, fostering innovation and ensuring a competitive market landscape. The CCP's approval underlines its commitment to upholding fair competition, benefiting consumers, and encouraging growth and investment in the industry.

<https://www.tlpnews.com/pfizers-assets-acquisition-ccp-grants-approval/>



Investify Pakistan

@investifypk

4-August-2024

Online



Investify Pakistan

@investifypk

The Competition Commission of Pakistan has approved Lucky Core Industries' acquisition of certain assets of Pfizer Pakistan Limited, including pharmaceutical products and trademarks.



7:00 PM · Aug 4, 2024 · 87 Views

<https://x.com/investifypk/status/1820097370631057723>

HEADLINES August 4, 2024

CCP greenlights Lucky Core Industries' acquisition of Pfizer Pakistan assets

Classified as a horizontal merger, this transaction is expected to slightly boost LCI's market presence across the relevant sectors



ISLAMABAD: The Competition Commission of Pakistan (CCP) has approved Lucky Core Industries' (LCI) acquisition of specific assets from Pfizer Pakistan Limited.

This deal, facilitated through a series of agreements including the Frame Agreement and Asset Purchase Agreements, involves several prominent pharmaceutical products and their registrations, manufacturing technology, know-how, and associated trademarks. The products include Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and Mycitracin.

LCI, a publicly traded company in Pakistan, specializes in the production of chemicals and pharmaceuticals. Pfizer Pakistan Limited, the seller, is a public unlisted company engaged in the manufacturing, importing, and marketing of pharmaceuticals within Pakistan. Its parent company, Pfizer Inc., is a publicly traded biopharmaceutical and biotechnology firm based in Delaware, USA.

The CCP's market analysis identified the relevant product markets as Antirheumatic Systemic, Vitamins, Systemic Corticosteroids, Cough & Cold Preparations, Antiprotozoal & Anthelmintic, and Topical Antibacterial & Antivirals, with Pakistan as the geographic market.

Classified as a horizontal merger, this transaction is expected to slightly boost LCI's market presence across the relevant sectors. The CCP concluded that the acquisition would not result in market dominance, leading to prompt approval.

This strategic move is set to advance technological capabilities in Pakistan's pharmaceutical industry, promoting innovation and maintaining a competitive market environment.



4-August-2024

Online



Startup Pakistan

676,395 followers

Contact us

1h • 🌐

+ Follow ...

The Competition Commission of Pakistan (CCP) has greenlit Lucky Core Industries' acquisition of key assets from Pfizer Pakistan Limited.

The deal includes well-known pharmaceuticals such as Ansaid, Ponstan, and Corex-D, along with their trademarks, manufacturing technology, and registrations.

This acquisition is part of a strategic move by [Lucky Core Industries](#), a major player in the chemical and pharmaceutical sectors in Pakistan.

Pfizer Pakistan Limited remains a key pharmaceutical market player under its parent company, Pfizer Inc.

#Pharmaceuticals #BusinessNews #Pakistan #CCP #IndustryAcquisition



https://www.linkedin.com/posts/startup-pakistan_pharmaceuticals-businessnews-pakistan-activity-7226436845717360640-CWDN/

کمپیشن کمیشن نے فائزر کے اثاثوں

کے حصول کی منظوری دیدی

اسلام آباد (نمائندہ خصوصی) کمپیشن کمیشن آف پاکستان (سی سی پی) نے لکی کور انڈسٹریز کو فائزر پاکستان لمیٹڈ کے بعض اثاثوں کے حصول کی منظوری دے دی ہے۔ یہ حصول سیٹ آف ایگریمنٹ کے ذریعے ہوا ہے جس میں فریم ایگریمنٹ اور اثاثہ کی خریداری کے ایگریمنٹ شامل ہیں۔ اس حصول میں کئی معروف دواسازی کی مصنوعات جیسا کہ اینیڈ، صفحہ 6 پر بقیہ نمبر 61

اثاثے/منظوری

بقیہ 61

پونشان، پونشان فورٹ، بیسولین، ڈیلٹ گورٹل، لانسوٹ، کوریکس-ڈی اور مائی سیٹراس کی متعلقہ رجسٹریشنز، مینوفیکچرنگ ٹیکنالوجی، جانکاری، اور متعلقہ ٹریڈ مارکس شامل ہیں۔ لکی کور انڈسٹریز، پاکستان میں درج پبلک لسٹڈ کمپنی ہے جو مختلف کیمیکلز اور فارماسیوٹیکلز کی تیاری میں مصروف ہے۔

سی سی پی کی فائزر کے اثاثوں کے حصول کی منظوری

جس میں فریم ایگریمنٹ اور اثاثہ کی خریداری کے ایگریمنٹ شامل ہیں، ذرائع

دو سازی کی مصنوعات تیار، درآمد اور مارکیٹنگ کا کام کرتی ہے۔ سی سی پی کی مارکیٹ ایسیمنٹ نے متعلقہ مصنوعات کی مارکیٹوں کی شناخت اینٹی ہیومیٹک سیسٹیمیٹک، وٹامنز، سیسٹیمیٹک کورٹیکو سٹیرائڈز، کھانسی اور سردی کی تیاری، اینٹی پروٹوزول اور اینٹی ہیلپٹک، اور ٹاپیکل اینٹی بیکٹیریل اور اینٹی وائرلز کے طور پر کی ہے، جو کہ پاکستان کی جغرافیائی مارکیٹ میں ہے۔ اس ٹرانزیکشن کی افقی مرجر کے طور پر درجہ بندی کی گئی ہے، جس کے نتیجے میں متعلقہ مارکیٹوں میں لگی کور انڈسٹریز کی مارکیٹ میں موجودگی میں معمولی اضافہ ہوا ہے۔ سی سی پی جائزے کے مطابق یہ حصول مارکیٹ میں بالادستی کا باعث نہیں بنے گا۔ یہ اسٹریٹجک حصول پاکستان کے فارماسیوٹیکل سیکٹر میں تکنیکی ترقی کو بڑھانیا اور جدت کو فروغ دینے کا باعث ہوگا۔

اسلام آباد (سٹاف رپورٹر) کمپنیشن کمیشن آف پاکستان (سی سی پی) نے لگی کور انڈسٹریز کو فائزر پاکستان لمیٹڈ کے بعض اثاثوں کے حصول کی منظوری دے دی ہے۔ یہ حصول سیٹ آف ایگریمنٹ کے ذریعے ہوا ہے جس میں فریم ایگریمنٹ اور اثاثہ کی خریداری کے ایگریمنٹ شامل ہیں۔ اس حصول میں کئی معروف دو سازی کی مصنوعات جیسا کہ اینسیڈ، پونشان، پونشان فورٹ، بیسوکین، ڈیلٹا کورٹل، لاسوٹ، کوریکس-ڈی اور مائی سیٹراسن کی متعلقہ رجسٹریشنز، مینوفیکچرنگ ٹیکنالوجی، جانکاری، اور متعلقہ ٹریڈ مارکس شامل ہیں۔ لگی کور انڈسٹریز، پاکستان میں درج پبلک لسٹڈ کمپنی ہے جو مختلف کیمیکلز اور فارماسیوٹیکلز کی تیاری میں مصروف ہے۔ جبکہ فائزر پاکستان لمیٹڈ ایک پبلک آن لسٹڈ کمپنی ہے جو پاکستان میں

سی سی پی کی فاترز کے اثاثوں کے حصول کی منظوری

لکی کور انڈسٹریز کو فاترز پاکستان لمیٹڈ کے بعض اثاثوں کے حصول کی منظوری دی گئی

اسلام آباد (کامر رپورٹر) کمپنیشن کمیشن آف پاکستان (سی سی پی) نے لکی کور انڈسٹریز کو فاترز پاکستان لمیٹڈ کے بعض اثاثوں کے حصول کی منظوری دے دی ہے۔ یہ حصول سیٹ آف ایگریمنٹ کے ذریعے ہوا ہے جس میں فریم ایگریمنٹ اور اثاثہ کی خریداری کے ایگریمنٹ شامل ہیں۔ اس (باقی صفحہ 5 بقیہ نمبر 38)



حصول میں کئی معروف دواسازی کی مصنوعات جیسا کہ اینسڈ، پونشان، پونشان فورٹ، بیسوکین، ڈیلٹا کورٹل، لاسوٹ، کوریکس-ڈی اور مائی سپران کی متعلقہ رجسٹریشنز، مینوفیکچرنگ میکانولوجی، چانکاری، اور متعلقہ ٹریڈ مارکس شامل ہیں۔ لکی کور انڈسٹریز، پاکستان میں درج پبلک لسٹڈ کمپنی ہے جو مختلف کمپنیز اور فارماسیوٹیکلز کی تیاری میں مصروف ہے۔ جبکہ فاترز پاکستان لمیٹڈ ایک پبلک ان لسٹڈ کمپنی ہے جو پاکستان میں دواسازی کی مصنوعات تیار، درآمد اور مارکیٹنگ کا کام کرتی ہے۔ سی سی پی کی مارکیٹ ایسیمنٹ نے متعلقہ مصنوعات کی مارکیٹوں کی شناخت انٹی ہیبوٹیک سیسٹیمیک، وٹامنز، سیسٹیمیک کورٹیکو سٹیرائڈز، کھانسی اور سردی کی تیاری، اینٹی پروٹوزول اور اینٹی بیکٹیک، اور ٹائپیکل اینٹی بییکٹیریل اور اینٹی وائرس کے طور پر کی ہے، جو کہ پاکستان کی جغرافیائی مارکیٹ میں ہے۔

لکی کور انڈسٹریز کو فائزر پاکستان کے
بعض اثاثوں کے حصول کی منظوری

اسلام آباد (جہان پاکستان نیوز) کمپنیشن کمیشن
آف پاکستان (سی سی پی) نے لکی کور انڈسٹریز کو
فائزر پاکستان لمیٹڈ کے بعض اثاثوں کے حصول کی
منظوری دے (باقی صفحہ 6 بقیہ نمبر 42)

43

بقیہ

اینٹی بائیوٹک ادویات تجویز کرنے والے ڈاکٹروں
کے خلاف بھی ایکشن تجویز کریں گے کام کے مطابق
ادویات کی فروخت کیلئے غیر اخلاقی مارکیٹنگ کرنے
والی فارما کمپنیوں کے خلاف بھی ایکشن لیں گے۔

(Sindhi)

4-August-2024

Page # 6

سي سي پي طرفان لڪي ڪور انڊسٽريز کي فائز جا ڪجهه اثاڻا حاصل ڪرڻ جي منظوري

هن معاهدي ۾ سيٽ آف ايگريمينٽ ۽ اثاڻن جي خريداري جي ايگريمينٽ پڻ شامل آهي

ايگريمينٽ شامل آهن، هن معاهدي ۾ ڪيٽريون ٿي دواسازي جون مصنوعات جهڙوڪ اينسڊ، پونسٽان، پونسٽان فورٽ، بيسوڪين، ڊيلٽا ڪورٽل، لائسو وٽ، ڪوريڪس ڊي ۽ مائي سيٽراسن جي ڄاڻايل رجسٽريشنز، مينيو فيڪچرنگ، ٽيڪنالوجي ۽ ٽريڊ مارڪس شامل آهن

اسلام آباد (پ ر) ڪمپيٽيشن ڪميشن آف پاڪستان (سي سي پي) لڪي ڪور انڊسٽريز کي فائز پاڪستان جا ڪجهه اثاڻا حاصل ڪرڻ جي منظوري ڏئي ڇڏي آهي، هي معاهدو سيٽ آف ايگريمينٽ جي ذريعي ٿيو آهي جنهن ۾ فريم ايگريمينٽ ۽ اثاڻن جي خريداري جا

سی سی پی کی منظوری سے لکی کور نے فاتر کے اثاثے حاصل کر لیے

ریکارڈر رپورٹ شائع August 4, 2024

مسابقتی کمیشن آف پاکستان (سی سی پی) نے لکی کور انڈسٹریز کی جانب سے فاتر پاکستان لمیٹڈ کے کچھ اثاثے حاصل کرنے کی منظوری دے دی ہے۔ اس حصول کو فریم معاہدے اور اثاثوں کی خریداری کے معاہدوں سمیت معاہدوں کے ایک سیٹ کے ذریعہ سہولت فراہم کی جارہی ہے۔

اس حصول میں متعدد معروف فارماسیوٹیکل مصنوعات اور ان کی متعلقہ رجسٹریشنز، مینوفیکچرنگ ٹیکنالوجی، معلومات اور انسٹالیشن، پوسٹن فورٹ، باسوکوٹین، ڈیلٹا کورٹریل، لیسوریت، کوریکس-ڈی، اور مائکٹریسین کے لئے متعلقہ ٹریڈ مارک شامل ہیں۔

لکی کور انڈسٹریز پاکستان میں پبلک لسٹڈ کمپنی ہے جو مختلف کیمیکلز اور فارماسیوٹیکلز کی مینوفیکچرنگ کرتی ہے۔

دی سیار، فاتر پاکستان لمیٹڈ، ایک عوامی غیر لسٹڈ کمپنی ہے جو پاکستان میں دواسازی کی مصنوعات تیار، درآمد اور مارکیٹ کرتی ہے۔ اس کی پیرنٹ کمپنی میسنز فاتر انکارپوریٹڈ امریکہ کے شہر ڈیلاویئر میں واقع ایک پبلک لسٹڈ ہائیو فارماسیوٹیکل اور ہائیو ٹیکنالوجی کمپنی ہے۔

سی سی پی کے مارکیٹ جائزے میں متعلقہ مصنوعات کی مارکیٹوں کی نشاندہی اینٹی ریومیٹک سٹمک، وٹامنز، سٹمک کورٹیکوسٹیروائڈز، کھانسی اور سردی کی روک تھام، اینٹی پروٹوزول اینڈ اینٹیہلمینٹک، اور ٹاپیکل اینٹی بیکٹیریل اینڈ اینٹی وائرلز کے طور پر کی گئی ہے، جس کی مارکیٹ پاکستان ہے۔

اس لین دین کے نتیجے میں متعلقہ مارکیٹوں میں لکی کور انڈسٹریز کی مارکیٹ موجودگی میں معمولی اضافہ ہوا ہے۔

سی سی پی نے فیصلہ کیا ہے کہ اس حصول سے کسی بھی مارکیٹ میں غلبہ حاصل نہیں ہوگا، اس طرح فوری منظوری مل جائے گی۔

اس اسٹریٹجک حصول سے پاکستان کے فارماسیوٹیکل سیکٹر میں تکنیکی ترقی میں اضافہ ہوگا، جدت طرازی کو فروغ ملے گا اور مسابقتی مارکیٹ کے منظر نامے کو یقینی بنایا جائے گا۔

سی سی پی کی منظوری منصفانہ مسابقت کو برقرار رکھنے، صارفین کو فائدہ پہنچانے اور صنعت میں ترقی اور سرمایہ کاری کی حوصلہ افزائی کرنے کے اس کے عزم کی عکاسی کرتی ہے۔

کاپی رائٹ بزنس ریکارڈر، 2024